[Revision of failed dacryocystorhinostomies using the transcanalicular approach. Results of 118 procedures].
OBJECTIVE
To assess the efficacy of transcanalicular dacryocystorhinostomy for the revision of other procedures. The results are analyzed following the use of two different types of laser: the Neodymium: YAG (Nd: YAG) laser and the Holmium: YAG (Ho: YAG) laser. To study the efficacy of using two antimetabolite drugs in this context: mytomycin-C (MMC) and 5-fluoro-uracile (5-FU).


METHODS
One hundred and fourteen patients were operated on. Of these, 88 had already undergone one procedure, 25 two procedures, and 5 three procedures. The Nd: YAG laser was used in 78 procedures, the Ho: YAG in 30 procedures, and both lasers in 10 procedures. Twenty patients were treated with an application of MMC and 25 patients with an application of 5-FU.


RESULTS
The results are based on 106 procedures. The total success rate was 49.06% after one revision and 58.49% after two or three revisions. There is no statistically significant difference between the Nd: YAG and Ho: YAG lasers. The use of antimetabolites did not improve the success rate.


CONCLUSIONS
Transcanalicular dacryocystorhinostomy is a very useful method because it does not cause cutaneous scarring and it has a low rate of morbidity given that it causes very little surgical traumatism. The revision of other dacryocystorhinostomy methods using the transcanalicular approach is theoretically a positive indication because it does not dissect scarring tissues and because the osteotomy has already been performed. However, the success rate is lower than for the external and endonasal approaches. The success rate is not modified by the use of antimetabolites or by the type of laser.
Piaton
J M
JM
Centre National d'Ophtalmologie des Quinze-Vingts, Service du professeur S. Limon, 28, Rue de Charenton, 75012 Paris, France.
Keller
P
P
Limon
S
S
Quenot
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000477:Alkylating Agents / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D003608:Dacryocystorhinostomy / Q000379:methods*; D003627:Data Interpretation, Statistical; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006695:Holmium; D006801:Humans; D007431:Intraoperative Complications; D053685:Laser Therapy / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D009354:Neodymium; D011183:Postoperative Complications; D012086:Reoperation; D013997:Time Factors
D000477:Alkylating Agents; D000963:Antimetabolites; D009354:Neodymium; D016685:Mitomycin; D005472:Fluorouracil; D006695:Holmium